Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Aclaris Therapeutics (DE:8AT)
FRANKFURT:8AT
Holding DE:8AT?
Track your performance easily
8AT Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.82 - €4.52
Previous Close€2.64
Volume0.00
Average Volume (3M)4.22K
Market Cap
€186.28M
Enterprise Value€68.08M
Total Cash (Recent Filing)$127.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta-1.00
Next Earnings
Feb 20, 2025EPS Estimate
-€0.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding71,430,942
10 Day Avg. Volume241
30 Day Avg. Volume4,217
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)1.45
Price to Sales (P/S)7.17
Price to Cash Flow (P/CF)2.20
P/FCF Ratio2.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue2.51
Enterprise Value/Gross Profit5.17
Enterprise Value/Ebitda-1.19
Forecast
1Y Price Target
€7.72Price Target Upside192.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Aclaris Therapeutics News
Bulls Say, Bears Say
Bulls Say
Analyst RecommendationAnalyst's recommendation for Aclaris Therapeutics Inc. has been upgraded to Outperform, indicating strong confidence in the company's potential.
Financial BackingAn $80 million private placement was announced to support the company's newly bolstered pipeline and operational efforts, showing strong investor interest and financial backing.
Pipeline DevelopmentThe acquisition of worldwide rights to two in-licensed biologics, BSI-045B and BSI-502, is expected to strengthen Aclaris Therapeutics Inc.'s immunology-focused pipeline.
Bears Say
Clinical And Regulatory RisksThere are clinical, regulatory, and commercial risks associated with Aclaris Therapeutics' pipeline products.
Strategic ReviewACRS initiated a company-wide strategic review following disappointing data from zunsemetinib in rheumatoid arthritis (RA) and hidradenitis suppurativa (HS), where both trials failed to achieve primary and key secondary endpoints.
Uncertainty In Future DevelopmentsOverall, the analysis remains on the sidelines pending any further updates on the strategic review, early data from the POC study of ATI-2138 in AD, and progress regarding strategic partnerships.
---
8AT FAQ
What was Aclaris Therapeutics’s price range in the past 12 months?
Aclaris Therapeutics lowest stock price was €0.82 and its highest was €4.52 in the past 12 months.
What is Aclaris Therapeutics’s market cap?
Currently, no data Available
When is Aclaris Therapeutics’s upcoming earnings report date?
Aclaris Therapeutics’s upcoming earnings report date is Feb 20, 2025 which is in 60 days.
How were Aclaris Therapeutics’s earnings last quarter?
Aclaris Therapeutics released its earnings results on Nov 06, 2024. The company reported -€0.105 earnings per share for the quarter, missing the consensus estimate of -€0.006 by -€0.099.
Is Aclaris Therapeutics overvalued?
According to Wall Street analysts Aclaris Therapeutics’s price is currently Undervalued.
Does Aclaris Therapeutics pay dividends?
Aclaris Therapeutics does not currently pay dividends.
What is Aclaris Therapeutics’s EPS estimate?
Aclaris Therapeutics’s EPS estimate is -€0.28.
How many shares outstanding does Aclaris Therapeutics have?
Aclaris Therapeutics has 71,430,940 shares outstanding.
What happened to Aclaris Therapeutics’s price movement after its last earnings report?
Aclaris Therapeutics reported an EPS of -€0.105 in its last earnings report, missing expectations of -€0.006. Following the earnings report the stock price went down -0.878%.
Which hedge fund is a major shareholder of Aclaris Therapeutics?
Among the largest hedge funds holding Aclaris Therapeutics’s share is Aisling Capital Management LP. It holds Aclaris Therapeutics’s shares valued at N/A.
---
Aclaris Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€7.72 (192.16% Upside)
€7.72 (192.16% Upside)
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
190.90%
12-Months-Change
Fundamentals
Return on Equity
-25.83%
Trailing 12-Months
Asset Growth
-16.47%
Trailing 12-Months
Company Description
Aclaris Therapeutics
Aclaris Therapeutics, Inc. operates as a dermatologist-led biopharmaceutical company, which engages in identifying, developing, and commercializing novel drugs to address the needs in medical and aesthetic dermatology and immunology. It operates through Therapeutics and Contract Research segments. The Therapeutics segment focuses in identifying, developing, and commercializing innovative and differentiated therapies to address significant unmet needs in medical and aesthetic dermatology. The Contract Research segment provides laboratory services under contract research arrangements to pharmaceutical and biotech companies. The company was founded by Neal S. Walker, Frank Ruffo, Kamil Ali-Jackson, Christopher V. Powala, and Stuart D. Shanler in July 2012 and is headquartered in Malvern, PA.
---
8AT Company Deck
---
8AT Earnings Call
Q1 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlights Aclaris' strong financial position and promising advancement of ATI-2138, despite some challenges in cash reserves and competitive landscape considerations. The company is making strategic moves in its drug development with a focus on efficiency and differentiation.Read More>---
8AT Stock 12 Month Forecast
Average Price Target
€7.72
▲(192.16% Upside)
Technical Analysis
Aclaris Therapeutics
―
AnaptysBio
―
Chimerix
―
EyePoint Pharmaceuticals
―
Fate Therapeutics
―
Best Analysts Covering 8AT
1 Year
1 Year Success Rate
2/11 ratings generated profit
1 Year Average Return
-29.66%
reiterated a buy rating 5 days ago
Copying Roger Song's trades and holding each position for 1 Year would result in 18.18% of your transactions generating a profit, with an average return of -29.66% per trade.
---